|Bid||117.04 x 400|
|Ask||117.14 x 600|
|Day's Range||112.13 - 118.30|
|52 Week Range||31.38 - 118.40|
|PE Ratio (TTM)||-22.85|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It’s been a big week for the gene therapy universe. Of course, there’s the latest Barron’s cover story, which details the emerging medical revolution and highlights three stocks -- AveXis (AVXS), Regenxbio (RGNX), and Spark Therapeutics (ONCE) -- that have big stakes in what is widely considered one of the most exciting areas in the biotechnology arena. Last week, Ultragenyx Pharmaceutical (RARE) offered to buy Dimension Therapeutics (DMTX) for at $5.50 per share in cash.
Q2 2017 Alnylam Pharmaceuticals Inc Earnings Call
Why Madrigal, Alnylam, and Arbutus Biopharma stocks were this week's biggest biotech winners.